{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:35:53Z","timestamp":1771014953674,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:00:00Z","timestamp":1503446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.clinthera.2017.08.010","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T14:15:22Z","timestamp":1506608122000},"page":"1986-2005.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed\u2013refractory Multiple Myeloma in the United States"],"prefix":"10.1016","volume":"39","author":[{"given":"Christopher G.","family":"Pelligra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kejal","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shien","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1365-9002","authenticated-orcid":false,"given":"Conor","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5978-9411","authenticated-orcid":false,"given":"Jorge","family":"Mouro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safiya","family":"Abouzaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.08.010_bib1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.08.010_bib2","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Guidelines: Multiple Myeloma. Version 3. 2016 (subscription needed). [cited 2016 September 2]. https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/myeloma.pdf"},{"key":"10.1016\/j.clinthera.2017.08.010_bib3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","article-title":"The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinthera.2017.08.010_bib4","unstructured":"National Cancer Institute, Surveillance Epidemiology and End Results (SEER) Program. SEER Stat Fact Sheets: Myeloma [cited 2016 September 2]. http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"10.1016\/j.clinthera.2017.08.010_bib5","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/bcj.2011.34","article-title":"Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score","volume":"1","author":"Kleber","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clinthera.2017.08.010_bib6","doi-asserted-by":"crossref","unstructured":"Rizzo M, Xu Y, Panjabi S. Poster No. PCN81: A Systematic Literature Review of the Economic Burden in Multiple Myeloma, 2014. ISPOR 17th Annual European Congress, Amsterdam, the Netherlands; 2014","DOI":"10.1016\/j.jval.2014.08.2239"},{"key":"10.1016\/j.clinthera.2017.08.010_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2017.08.010_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.18553\/jmcp.2008.14.S7-A.19","article-title":"Economic and clinical impact of multiple myeloma to managed care","volume":"14","author":"Cook","year":"2008","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.clinthera.2017.08.010_bib9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2017.08.010_bib10","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3109\/10428194.2013.827188","article-title":"Recent improvement in survival of patients with multiple myeloma: variation by ethnicity","volume":"55","author":"Pulte","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clinthera.2017.08.010_bib11","author":"Howlader","year":"2016","journal-title":"SEER Cancer Statistics Review, 1975-2013"},{"key":"10.1016\/j.clinthera.2017.08.010_bib12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk for progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2017.08.010_bib13","unstructured":"Kyprolis (carfilzomib) for injection, for intravenous use [prescribing information]. 2012 [cited 2016 September 2]. Onyx Pharmaceuticals. http:\/\/pi.amgen.com\/united_states\/kyprolis\/kyprolis_pi.pdf"},{"key":"10.1016\/j.clinthera.2017.08.010_bib14","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2017.08.010_bib15","unstructured":"Pomalyst (pomalidomide) capsules, for oral use [prescribing information]. 2013 [cited 2016 September 2]. Celgene Corporation. http:\/\/www.celgene.com\/content\/uploads\/pomalyst-pi.pdf"},{"key":"10.1016\/j.clinthera.2017.08.010_bib16","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2017.08.010_bib17","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2017.08.010_bib18","unstructured":"Darzalex (daratumumab) injection, for intravenous use [prescribing information]. 2015 [cited 2016 September 2]. Janssen Biotech. https:\/\/www.darzalex.com\/shared\/product\/darzalex\/darzalex-prescribing-information.pdf"},{"key":"10.1016\/j.clinthera.2017.08.010_bib19","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.08.010_bib20","first-page":"204","article-title":"Estimating the costs of therapy in patients with relapsed and\/or refractory multiple myeloma: a model framework","volume":"8","author":"Roy","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.clinthera.2017.08.010_bib21","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/13696998.2016.1194278","article-title":"Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective","volume":"19","author":"Jakubowiak","year":"2016","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2017.08.010_bib22","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3109\/0284186X.2015.1096021","article-title":"Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden","volume":"55","author":"Borg","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clinthera.2017.08.010_bib23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.18553\/jmcp.2016.22.8.991","article-title":"Estimating the economic impact of adding panobinostat to a U.S. formulary for relapsed and\/or refractory multiple myeloma: a budget impact and cost-benefit model","volume":"22","author":"Bloudek","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2017.08.010_bib24","series-title":"Cost effectiveness in health and medicine","author":"Neumann","year":"2017"},{"key":"10.1016\/j.clinthera.2017.08.010_bib25","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40273-015-0271-1","article-title":"Simulation and matching-based approaches for indirect comparison of treatments","volume":"33","author":"Ishak","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2017.08.010_bib26","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2017.08.010_bib27","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2017.08.010_bib28","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.clinthera.2017.08.010_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/00019053-200725010-00002","article-title":"Rates and probabilities in economic modelling: transformation, translation and appropriate application","volume":"25","author":"Fleurence","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2017.08.010_bib30","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.jval.2011.04.004","article-title":"A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer","volume":"14","author":"Goulart","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2017.08.010_bib31","doi-asserted-by":"crossref","first-page":"472","DOI":"10.18553\/jmcp.2006.12.6.472","article-title":"Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan","volume":"12","author":"Ramsey","year":"2006","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.clinthera.2017.08.010_bib32","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40273-013-0064-3","article-title":"Overview of parametric survival analysis for health-economic applications","volume":"31","author":"Ishak","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2017.08.010_bib33","unstructured":"Truven Health Analytics. Red Book. [cited 2016 September 2]. http:\/\/micromedex.com\/products\/product-suites\/clinical-knowledge\/redbook"},{"key":"10.1016\/j.clinthera.2017.08.010_bib34","unstructured":"United States Centers for Medicare & Medicaid Services. July 16 ASP Pricing File. [cited 2016 September 2]. https:\/\/www.cms.gov\/apps\/ama\/license.asp?file=\/medicare\/medicare-fee-for-service-part-b-drugs\/mcrpartbdrugavgsalesprice\/downloads\/2016-july-asp-pricing-file.zip"},{"key":"10.1016\/j.clinthera.2017.08.010_bib35","year":"2016","journal-title":"Physician Fee Schedule. Year 2016. National Payment Amount by HCPCS Code"},{"key":"10.1016\/j.clinthera.2017.08.010_bib36","year":"2016","journal-title":"Hospital Outpatient PPS. Payment by HCPCS Code for CY 2016"},{"key":"10.1016\/j.clinthera.2017.08.010_bib37","unstructured":"National Institute for Health and Care Excellence (NICE). NICE Technology Appraisal Guidance [TA338]: Pomalidomide for Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib 2015 [cited 2016 September 2]. https:\/\/www.nice.org.uk\/guidance\/ta338?unlid=51471159201611023313"},{"key":"10.1016\/j.clinthera.2017.08.010_bib38","year":"2016","journal-title":"Clinical Diagnostic Laboratory Fee Schedule. National Payment Limit by HCPCS code"},{"key":"10.1016\/j.clinthera.2017.08.010_bib39","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","article-title":"AdViSHE: A validation-assessment tool of health-economic models for decision makers and model users","volume":"34","author":"Vemer","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2017.08.010_bib40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3111\/13696998.2015.1115407","article-title":"Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma","volume":"19","author":"Usmani","year":"2016","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2017.08.010_bib41","doi-asserted-by":"crossref","first-page":"236","DOI":"10.18553\/jmcp.2017.23.2.236","article-title":"Real-world treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or carfilzomib","volume":"23","author":"Chen","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2017.08.010_bib42","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1200\/JCO.2005.05.3959","article-title":"Adverse event reporting in publications compared with sponsor database for cancer clinical trials","volume":"24","author":"Scharf","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817308998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817308998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T16:35:51Z","timestamp":1659544551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817308998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0149291817308998"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.08.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed\u2013refractory Multiple Myeloma in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}